A Common, Often Silent Condition
Chronic kidney disease (CKD) affects roughly 15 percent of adults in the United States. The vast majority — possibly 90 percent — don't know they have it. CKD progresses silently for years before causing symptoms, and by the time symptoms emerge, much of the irreversible damage has already occurred.
Identifying and treating CKD early is one of the highest-yield activities in primary care. The treatment landscape has changed substantially in the past few years with the introduction of SGLT2 inhibitors as kidney-protective drugs even in patients without diabetes.
At Zimmer Medical Group, we screen patients at risk for CKD and use current guidelines to slow progression aggressively.
What Your Kidneys Do
The kidneys serve multiple functions:
- Filter waste from blood
- Manage fluid and electrolyte balance
- Regulate blood pressure
- Produce hormones for red blood cell production (erythropoietin)
- Activate vitamin D for bone health
- Clear medications
When kidney function declines, all of these are affected — often subtly at first.
Understanding eGFR
Estimated glomerular filtration rate (eGFR) is the standard measure of kidney function. It estimates how much blood the kidneys filter per minute and is calculated from blood creatinine plus age and sex (the most current 2021 CKD-EPI equation no longer uses race in the calculation).
CKD stages by eGFR:
- Stage 1: eGFR ≥ 90 with kidney damage (protein in urine, abnormal imaging, etc.)
- Stage 2: eGFR 60–89 with kidney damage
- Stage 3a: eGFR 45–59
- Stage 3b: eGFR 30–44
- Stage 4: eGFR 15–29
- Stage 5 (kidney failure): eGFR < 15 or on dialysis
eGFR can be reported as "> 60" rather than a specific number when kidney function is in the normal range — modern labs do this because the equations are less precise at higher values.
Why Urine Protein Matters
eGFR alone doesn't capture the full picture. Albuminuria (protein in urine) is at least as important and often more so. The standard test is the urine albumin-to-creatinine ratio (UACR):
- A1 (normal): UACR < 30 mg/g
- A2 (moderately increased): UACR 30–300 mg/g
- A3 (severely increased): UACR > 300 mg/g
Albuminuria reflects damage to the kidney's filtering structures. Patients with normal eGFR but significant albuminuria still have CKD and elevated cardiovascular risk. Conversely, treatments that reduce albuminuria slow kidney disease progression.
Who Should Be Screened
Annual screening (eGFR plus UACR) is recommended for adults with:
- Diabetes
- Hypertension
- Cardiovascular disease (CAD, PAD, heart failure, stroke)
- Family history of CKD
- Age ≥ 60
- History of acute kidney injury
- Long-term use of nephrotoxic medications (NSAIDs, certain antibiotics)
- Personal history of preeclampsia
- Black, Native American, or Hispanic ethnicity (higher CKD risk)
Common Causes of CKD
The leading causes in the US:
- Diabetes (about 1/3 of cases)
- Hypertension (about 1/4 of cases)
- Glomerulonephritis (autoimmune kidney disease)
- Polycystic kidney disease and other genetic conditions
- Chronic obstructive uropathy (BPH, kidney stones)
- Recurrent infections
- Chronic NSAID use
- Recurrent acute kidney injury
- Vasculitis
In many patients, multiple contributors coexist.
Why CKD Matters Beyond the Kidneys
Patients with CKD have:
- 2–10 times the cardiovascular mortality of age-matched controls (most patients with CKD die of cardiovascular disease, not kidney failure)
- Higher rates of stroke, heart failure, and atrial fibrillation
- Increased risk of bone disease and fractures
- Higher infection risk
- Anemia from reduced erythropoietin
- Greater risk of medication adverse effects
This is why CKD treatment focuses heavily on cardiovascular risk reduction in addition to slowing kidney decline.
The Modern Treatment Stack
1. Tight Blood Pressure Control
Target generally < 130/80 in CKD patients. Medications matter:
- ACE inhibitors or ARBs — first-line for CKD with albuminuria; reduce both blood pressure and protein leakage
- Use one of these unless contraindicated
- Monitor potassium and kidney function after starting
2. SGLT2 Inhibitors (The Game Changer)
SGLT2 inhibitors (empagliflozin, dapagliflozin) were originally diabetes drugs but are now established kidney-protective medications even in patients without diabetes:
- Slow CKD progression by 30–40 percent in trials
- Reduce hospitalization for heart failure
- Reduce cardiovascular events
- FDA-approved for CKD regardless of diabetes status
- Recommended in current KDIGO guidelines for most adults with CKD
This represents the most significant CKD treatment advance in decades.
3. Diabetes Optimization
For patients with diabetes:
- Tight glycemic control (typically A1C < 7 in most adults; less stringent in older or frail patients)
- SGLT2 inhibitor and/or GLP-1 receptor agonist for kidney protection
- Avoid metformin if eGFR < 30; use cautiously between 30–45
4. Address Cardiovascular Risk
- High-intensity statin therapy in most CKD patients
- Antiplatelet therapy when indicated
- Aggressive lipid management
5. Avoid Nephrotoxic Medications
- Limit chronic NSAID use (try acetaminophen, topical NSAIDs for chronic pain — see non-opioid pain management)
- Adjust doses of medications that depend on kidney clearance
- Avoid IV contrast when possible; alternative imaging when feasible
- Be cautious with certain antibiotics (gentamicin, vancomycin) and immunosuppressants
6. Address Complications as They Develop
- Anemia management
- Bone and mineral disorder management (calcium, phosphorus, parathyroid hormone)
- Acidosis correction
- Hyperkalemia management
7. Lifestyle Measures
- Mediterranean-style diet
- Sodium restriction
- Adequate but not excessive protein intake
- Regular physical activity
- Smoking cessation
- Weight management
- Limit alcohol
When to Refer to Nephrology
Most early-stage CKD is managed in primary care. Nephrology referral is appropriate for:
- eGFR < 30 (stage 4 or 5)
- Rapid decline in kidney function
- Significant proteinuria (UACR > 300 mg/g)
- Hematuria with proteinuria suggesting glomerular disease
- Difficult-to-control blood pressure
- Hyperkalemia despite optimal management
- Suspected hereditary or autoimmune kidney disease
- Preparation for renal replacement therapy
What Patients Should Know
- CKD is common and often silent — get tested if you have risk factors
- The single most important thing is identifying it early
- Modern treatment can dramatically slow progression — many patients stable for decades
- Kidney function is closely tied to heart health
- Most CKD patients die of cardiovascular disease, so cardiovascular risk reduction matters as much as kidney protection
- A few medications (especially NSAIDs) can accelerate decline
- Hydration matters but more isn't always better — discuss specific fluid recommendations with your doctor
When to See Your Doctor
- Risk factors for CKD (diabetes, hypertension, family history)
- Foamy urine
- New leg swelling
- Decreased urination
- Persistent fatigue
- Discovered abnormal kidney function on routine labs
The National Kidney Foundation provides extensive patient resources, and the KDIGO guidelines inform current clinical practice.
Have risk factors for kidney disease or unsure where your numbers stand? Contact Zimmer Medical Group for testing, comprehensive evaluation, and the modern treatment plan that protects both your kidneys and your heart.
